Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

112,918 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced Biliary Tract Cancers: an open-label, single-arm, phase II clinical trial.
Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, Jiang G, Chen R, Han J, Jiang M, Qiao S, Liu J, Song M, Song L, Du Y, Chang Z, Wang M, Dong M, Zhong Y, Yu P, Zhang X, Zong H. Jin S, et al. Among authors: liu j. Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34372. Online ahead of print. Int J Cancer. 2022. PMID: 36444498
[Application of isotemporal substitution model in epidemiological research].
Wang YT, Liu HM, Cao SX, Xu K, Zhang BY, Huo YT, Liu JC, Zeng LX, Dang SN, Yan H, Mi BB. Wang YT, et al. Among authors: liu jc. Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Nov 10;43(11):1842-1847. doi: 10.3760/cma.j.cn112338-20220210-00108. Zhonghua Liu Xing Bing Xue Za Zhi. 2022. PMID: 36444471 Chinese.
112,918 results
You have reached the last available page of results. Please see the User Guide for more information.